Table 4.
Clinical remission rates in adults with CD treated with EEN.
| Reference (Year of Publication) (Ref) |
N | Formula | T | Remission Criteria | R |
|---|---|---|---|---|---|
| O’Morain 1 (1984) [14] | 11 | E | 4 | H-B | 80% |
| Giaffer 2 (1990) [108] | 14 | P | 4 | CDAI | 36% |
| 16 | E | 75% | |||
| Malchow 1 (1990) [109] | 51 | P | 3–6 | CDAI | 41% |
| Lochs 1 (1991) [110] | 52 | P | 4–6 | CDAI | 55% |
| Rigaud 2 (1991) [111] | 15 | P | 4 | CDAI | 73% |
| 15 | E | 66% | |||
| Park 2 (1991) [112] | 7 | P | 4 | Simple activity index | 73% |
| 7 | E | 69% | |||
| Raouf 2 (1991) [113] | 11 | P | 3 | Simple activity index | 71% |
| 13 | E | 29% | |||
| Lindor 1 (1992) [114] | 9 | E | 4 | CDAI | 33% |
| González-Huix 1 (1993) [115] | 15 | P | 4 | Van Hess index | 80% |
| Gorard 1 (1993) [116] | 22 | E | 4 | Simple activity index | 32% |
| Royall 2 (1994) [117] | 19 | E | 3 | CDAI | 84% |
| 21 | O | 75% | |||
| Mansfield 2 (1995) [118] | 22 | O | 4 | CDAI | 36% |
| 22 | E | 36% | |||
| Verma 2 (2000) [119] | 11 | P | 4 | CDAI | 55% |
| 10 | E | 80% | |||
| Sakurai (2002) [120] | 36 | P | 6 | CDAI | 70% |
| Gassull 1 (2002) [121] | 43 | P | 4 | CDAI | 36% |
| Guo (2013) [122] | 13 | P | 4 | CDAI | 85% |
| Hu (2014) [67] | 59 | O | 12 | CDAI | 81% |
| Zhao (2015) [123] | 40 | P/O | 4 | CDAI | 52% |
| Yang (2017) [66] | 41 | NE | 12 | CDAI | 80% |
| Xue (2018) [124] | 67 | NE | 8 | CDAI | 68% |
| Xu (2019) [125] | 104 | NE | H-B | 52% | |
| Sharma (2020) [126] | 31 | P/S-E | 2–6 | CDAI | 80% |
| Total | 797 | IC (95%) | 60.1% (56.6–63.4) |
CDAI: Crohn’s disease activity index. 1: Clinical trials comparing with drugs. 2: Clinical trials comparing two enteral formulas. E: elemental formula. H-B: Harvey-Bradshaw. NE: not specified. O: oligomeric formula. P: polymeric formula.